Natalia Perekhvatova, the CEO of Mitotech S.A., is invited to present at the annual Sofinnova Japan Biopharma Partnering Conference held on 27 October in Tokyo.
"This is a great opportunity for Mitotech to present our latest achievements in U.S.-based clinical studies to Japanese pharmaceutical industry, said Natalia Perekhvatova, Chief Executive Officer of Mitotech S.A. “Japan is one of the leading markets in ophthalmic area in general and dry eye syndrome specifically, an indication where we have demonstrated excellent clinical progress to date.”
About Mitotech S.A
Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for treatment of age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria addressed antioxidants. Company's lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.